-
FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue
Thursday, May 29, 2025 - 12:42pm | 484The U.S. Food and Drug Administration (FDA) approved Eton Pharmaceuticals, Inc.’s (NASDAQ:ETON) new drug application (NDA) for Khindivi (hydrocortisone) oral solution as a replacement therapy for pediatric patients five years of age and older with adrenocortical insufficiency. Adrenocortical...
-
Vericel Analyst Projects Wound Care Product Sales Will Grow Fivefold By 2025
Wednesday, October 9, 2019 - 3:09pm | 446Vericel Corp (NASDAQ: VCEL), a commercial-stage company that specializes in advanced cell therapies for treating patients with knee cartilage defects and severe burn wounds, is investment-worthy, according to H.C. Wainwright. The Analyst Analyst Swayampakula Ramakanth initiated coverage of...
-
Cesca Therapeutics Snags Bullish HC Wainwright Initiation On CAR-T Opportunity
Wednesday, May 23, 2018 - 2:47pm | 415Cesca Therapeutics Inc (NASDAQ: KOOL) is poised to make much headway with its automated CAR-T manufacturing platform CAR-TXpress, according to H.C. Wainwright. CAR-T-cell therapy is a method of treating cancer by using a patient's immune system cells — T cells —...
-
For Eleven Biotherapeutics, Cancer Trial Outcomes Could Be 'Major Catalyst'
Tuesday, March 20, 2018 - 12:52pm | 297Eleven Biotherapeutics, Inc. (NASDAQ: EBIO), a Cambridge, Massachusetts-based developer of targeted protein therapeutics, has been showing promising clinical data for TPT-based cancer treatments. The stock could see significant upside if later-stage bladder cancer trials set for mid-2018 prove to...
-
Exclusive: RedHill Biopharma CEO Talks Steering His Company Through A Year Heavy With Potential Catalysts
Monday, June 5, 2017 - 3:54pm | 1228If investors were to sum up the year 2017 for specialty drug maker RedHill Biopharma Ltd - ADR (NASDAQ: RDHL) in one phrase, it might be this: “catalyst-rich.” A specialty biopharmaceutical company based in Israel, RedHill has a treasure trove of developing drugs in its pipeline to...
-
BioPharmX CFO Talks Clinical Pipeline Ahead Of Big Q2 Catalyst
Friday, March 31, 2017 - 12:08pm | 922Biopharmx Corp (NYSE: BPMX) shares have moved 38 percent higher in 2017 as the company progresses its dermatology-centric drugs through the pipeline. The Silicon Valley-based pharmaceutical currently has its lead candidate, BPX-01, undergoing both a Phase 2b dose finding trial for the treatment of...
-
HC Wainwright Bullish On Proteon Therapeutics, Sees 105% Potential Upside
Thursday, September 22, 2016 - 11:15am | 375HC Wainwright has initiated coverage of Proteon Therapeutics Inc (NASDAQ: PRTO) with a Buy rating and a price target of $18, representing a potential return of 105 percent. Proteon is developing a novel therapy to help prolong vascular access patency for dialysis patients. The company's lead...
-
H.C. Wainwright Sees Nearly 200% Upside In Vascular Biogenics
Tuesday, June 28, 2016 - 10:11am | 361H.C. Wainwright’s Swayampakula Ramakanth believes if the VTS gene therapy platform is successfully developed by Vascular Biogenics Ltd (NASDAQ: VBLT), it could revolutionize the multi-billion dollar angiogenesis inhibitor market. Ramakanth initiated coverage of the company with a Buy rating...
-
Cardiome Is A 'Rising Global Spec Pharma Play With Growth Potential'
Wednesday, June 1, 2016 - 12:10pm | 288H.C. Wainwright’s Swayampakula Ramakanth mentioned that CARDIOME PHARMA CORP (NASDAQ: CRME) “has an experienced in-hospital sales force and is developing a niche business model in the fragmented and difficult-to-operate $100B European hospital pharmacy market.” Ramakanth...
-
Why This Codexis Analyst Is Confident Stock Is Worth $6
Wednesday, January 6, 2016 - 1:51pm | 310H.C. Wainwright analysts Swayampakula Ramakanth and Sean Lee initiated coverage on Codexis, Inc. (NASDAQ: CDXS) with a Buy rating. The experts set a $6.00 price target, which implies an upside of more than 41 percent from current valuations. The main element supporting their bullish...
-
H.C. Wainwright: Time To Buy Novogen
Wednesday, July 1, 2015 - 9:06am | 323In a report published Wednesday, HC Wainwright analyst Swayampakula Ramakanth initiated coverage of Novogen Limited (ADR) (NASDAQ: NVGN) with a Buy rating and $8.50 price target. The company has three drug candidates that target an addressable market worth $38 billion and are expected to be...
-
RedHill Bio Price Target Boosted To $32, Buy Reiterated
Wednesday, June 17, 2015 - 9:00am | 261In a report published Wednesday, HC Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on RedHill Biopharma Ltd - ADR (NASDAQ: RDHL), while raising the price target from $23 to $32. The company announced on Tuesday that it had received UK regulatory approval to initiate the Phase 3...
-
UPDATE: H.C. Wainwright & Co. Initiates Coverage On MELA Sciences On Commercialization Strategy Change
Monday, August 18, 2014 - 9:12am | 224In a report published Monday, H.C. Wainwright & Co. analyst Swayampakula Ramakanth initiated coverage on MELA Sciences (NASDAQ: MELA) with a Buy rating and $4.50 price target. In the report, H.C. Wainwright & Co. noted, “MELA Sciences has developed a multi-spectral scanning device, MelaFind...
-
UPDATE: H.C. Wainwright Initiates Coverage On AEterna Zentaris
Thursday, July 17, 2014 - 8:51am | 140In a report released Thursday, H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage on AEterna Zentaris (NASDAQ: AEZS) with a Buy rating and a 12-month price target of $3.00 per share. Analysts at H.C. Wainwright favor AEterna for the likelihood of its drug Macrilen passing its FDA...